Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Mini Review Volume 4 Issue 10

Oral and Intravenous Iodine Treatment - A Hope to Treat 2019-nCoV Virus Infected Patients

Mohammad Azizur Rahman*

Professor of Respiratory Medicine, Under Faculty of Medicine, Dhaka University, Dhaka, Bangladesh

*Corresponding Author: Mohammad Azizur Rahman, Professor of Respiratory Medicine, Under Faculty of Medicine, Dhaka University, Dhaka, Bangladesh.

Received: July 14, 2020; Published: September 11, 2020



  To present intravenous iodine infusion (IVI) treatment, which has been used in serious bacterial infections in the past and has been off the agenda with widely used antibiotics. With the antiviral feature of iodine, to report the rationale of the use in patients with coronavirus infected and symptomatic patients. Also, to report the effective use of iodine therapy as an antiviral product that is safe, easy to use, easy to access and extremely cost-effective in the event of a possible excessive patient burden in hospitals.

Keywords: Intravenous Iodine Infusion (IVI); 2019-nCoV Virus



  1. Sattar SA., et al. “Chemical disinfection of non-porous inanimate surfaces experimentally contaminated with four human pathogenic viruses”. Epidemiology and Infection3 (1989): 493-505.
  2. “Relationship between virucidal efficacy and free iodine concentration of povidone iodine in buffer solutions”. Biocontrol Science 21.1 (2016): 21-27.
  3. Kariwa H., et al. “Inactivation of SARS Coronavirus by means of Povidone-Iodine, Physical Conditions and Chemical Reagents”. Dermatology1 (2006): 119-123.
  5. Lauer SA., et al. “The incubation period of Coronavirus Disease 2019 (Covid-19) from publicly confirmed cases: Estimation and application”. Annals of Internal Medicine 9 (2020): 577-582.
  6. Ferguson NM., et al. “Impact of non-pharmaceutical intervention (NPIs) to reduce Covid-19 mortality and healthcare demand”. Imperial College Covid-19 Response Team (2020).
  7. Yang Liu., et al. “Viral Dynamics in mild and severe cases of Covid-19”. The Lancet (2020).
  8. , et al. “Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity”. Emerging Microbes and Infections 9.1 (2020): 469-473.
  9. Gartner W and Weissel M. “Do iodine-containing contrast media induce clinically relevant changes in thyroid function parameters of euthyroid patients within the first week?” Thyroid 7 (2004): 521-524.
  10. Kuanrakcharoen P. “Radioiodine (1-131) Dose for the Treatment of Hyperthyroidism in Rajavithi Hospital”. Journal of the Medical Association of Thailand 2 (2016): S123-S129.
  11. Porter FJW. “A Plea for the More Frequent Use of Intravenous Medication with Special Reference to the Use of Iodine”. The Indian Medical Gazette 5 (1921): 161-162.
  12. Mukherjee PB. “Intravenous Iodine in the Treatment of Septic Wounds”. The Indian Medical Gazette11 (1923): 537-538.
  13. Connor FP. “The Use of Intravenous Injections of Iodine in the Treatment of Septicæmia and Other Septic Conditions”. Medicine Gaz3 (1924): 125-126.
  14. Jeudwine WW. “The Therapeutic Value of Intravenous Iodine. Based on Three Years' Experience on 400 Cases”. The Indian Medical Gazette 12 (1923): 561-571.
  15. De Castro. “Intravenous Iodine Injections”. The Indian Medical Gazette 3 (1925): 141.
  16. Bharadwaj AC. “The Treatment of Bubonic Plague with Intravenous Injections of Iodine”. The Indian Medical Gazette 2 (1926): 63-64.
  17. Yolcuoglu Burhan. Robert Cathcart (1992).
  18. Werbin N. “Polyvinyl pyrrolidone-iodine as an intravenous antiseptic”. Medical Hypotheses 2 (1985): 147-148.


Citation: Mohammad Azizur Rahman. “Oral and Intravenous Iodine Treatment - A Hope to Treat 2019-nCoV Virus Infected Patients". Acta Scientific Medical Sciences 4.10 (2020): 11-13.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

Contact US